MoonBiotech announced that it has recently completed a RMB 300 million Series C+ financing, solely invested by SDIC JULI Investment Management Co., LTD. This financing round follows the Series C funding involving SDIC Venture Capital, marking another instance of support from a national fund. The funds raised in this financing round will primarily be used to advance the large-scale production and commercialization of more innovative biological products, expand the company's proprietary commercial microbial strain and component libraries, and further enhance the biomanufacturing technology platform.

CEC Capital acted as the exclusive financial advisor for MoonBiotech in this transaction.

This round of financing is significant for SDIC Group’s strategic planning and promotion of the development of China's biomanufacturing industry.Biomanufacturing is a process that centers around industrial biotechnology, utilizing microbial cells, enzymes, and chemical engineering techniques to process target products. In this field, microbial chassis, genetic components, and enzyme molecules are the cornerstones of synthetic biology and biomanufacturing. They serve as the "chips" of the biomanufacturing industry, while diverse microbial strain resources are fundamental to discovering and developing new genetic components, new chassis strains, and new enzyme molecules. With the support of this financing round, MoonBiotech will continue to invest in the development of its proprietary microbial strain library and component libraries, striving to become a core driving force in China’s biomanufacturing industry and help build a new engine for the bioeconomy.